Management of patients refractory to platelet transfusion.
This article discusses the causes and management of platelet refractoriness. Improvements in the quality of platelets and leukoreduction have reduced the morbidity and mortality related to alloimmunization and refractoriness of patients to platelet transfusion. Alloimmunization can be distinguished from other causes of poor post-transfusion platelet increments by the measurement of platelet alloantibodies. Options for managing platelet refractoriness caused by alloimmunization include platelet transfusion from human leukocyte antigen-matched or donor-recipient cross-matched platelets. Prevention strategies include efforts to limit recipients' exposure to human leukocyte antigen specificities by using single-donor platelets, filtration to reduce the number of human leukocyte antigen-bearing leukocytes, and pretransfusion ultraviolet B irradiation to decrease their immunogenicity. For appropriate management of patients refractory to platelets, close cooperation and good communication are necessary between clinicians and blood centers.
Chockalingam
Porselvi
P
Hoxworth Blood Center, University of Cincinnati, OH 45267, USA.
Sacher
Ronald A
RA
D015119:Aminocaproic Acid / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001830:Body Surface Area; D015984:Causality; D006650:Histocompatibility Testing; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D009730:Nursing Assessment; D018579:Patient Selection; D010976:Platelet Count; D017713:Platelet Transfusion / Q000009:adverse effects / Q000379:methods; D017410:Practice Guidelines as Topic; D013921:Thrombocytopenia / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D013926:Thrombopoietin / Q000627:therapeutic use; D017211:Treatment Failure
D000933:Antifibrinolytic Agents; D007518:Isoantibodies; D013926:Thrombopoietin; D015119:Aminocaproic Acid